MOXISYLYTE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H25NO3
Molecular Weight	279.3746
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1

InChI

InChIKey=VRYMTAVOXVTQEF-UHFFFAOYSA-N

InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false http://www.ncbi.nlm.nih.gov/pubmed/1475074

Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459	Primary		Withdrawn	Unknown Approved Use Unknown
Diabetic retinopathy 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1475074	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of thymoxamine and pilocarpine on the depth of the anterior chamber.	1980 Oct	6449278
Effects of thymoxamine and its metabolites on clonidine-induced hypotension and bradycardia in rats.	1982 Jul	6215903
The esterase-like activity of serum albumin may be due to cholinesterase contamination.	2001 Oct	11697469
Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence.	2002	11948711
Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation.	2003 Aug	12897587
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats.	2006 Jan 30	16459151
Oral vasodilators for primary Raynaud's phenomenon.	2008 Apr 16	18425964
Noradrenergic control of GnRH release from the ewe hypothalamus in vitro: sensitivity to oestradiol.	2008 Dec	18484954
Raynaud's phenomenon (secondary).	2008 Sep 26	19445801
Effects of adrenergic agents on the expression of zebrafish (Danio rerio) vitellogenin Ao1.	2009 Jul 1	19371759

Patents

Sample Use Guides

In Vivo Use Guide

Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients

Route of Administration: Other

In Vitro Use Guide

Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction

Name

Type

Language

CARLYTENE

Preferred Name

English

MOXISYLYTE

Official Name

English

MOXISYLYTE [MI]

Common Name

English

(2-(4-ACETOXY-2-ISOPROPYL-5-METHYLPHENOXY)ETHYL)DIMETHYLAMINE

Systematic Name

English

6-ACETOXYTHYMOL 2-(DIMETHYLAMINO)ETHYL ETHER

Common Name

English

THYMOXAMINE

Common Name

English

Moxisylyte [WHO-DD]

Common Name

English

moxisylyte [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G04BE06